Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bisantrene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 8/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 4/20 | 1.00 |
| ▸ | HTR1A | P08908 | 2/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 1/20 | 1.00 |
| ▸ | NQO1 | P15559 | 1/20 | 1.00 |
| ▸ | DRD1 | P21728 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 1/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 0.62 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.56 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.56 |
| ▸ | ASIC1 | P78348 | 1/20 | 0.47 |
| ▸ | ADRA2C | P18825 | 6/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bisantrene SCHEMBL29398210 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL7207049 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL7472 | 1.00 | ADRA2A (1.00) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL1649622 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL17819003 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL2852448 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL29665174 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL4773 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| Bisantrene SCHEMBL17819004 | 0.98 | ADRA2A (0.97) | ADRA2AADRA1AHTR1ACHRM2ADORA3 | |
| SCHEMBL24610440 | 0.93 | ADRA2A (0.86) | ADRA2AADRA1AHTR1ACHRM2ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | RACE ONCOLOGY LTD (AU) | 2021-12-09 | — | — | US | disclosed |
| WO-2021016464-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | CITY OF HOPE (US) | 2021-01-28 | — | — | WO | disclosed |
| WO-2019073296-A1 | LIPOSOMAL FORMULATIONS OF BISANTRENE OR DERIVATIVES OR ANALOGS THEREOF | RACE ONCOLOGY LTD. (AU) | 2019-04-18 | — | — | WO | disclosed |
| US-7531162-B2 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
| US-7531162-B2 | Transcobalamin receptor binding conjugates useful for treating abnormal cellular proliferation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-12 | — | — | US | disclosed |
| US-5609867-A | POLYAMIDES FROM DIAMINE MONOMERS CONTAINING ANTHRAQUINONE, ANTHRAPYRAZOLE, AZA-ANTHRAQUINONE, AND DIAZA-ANTHRAQUINONE RINGS | AMERICAN CYANAMID COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| EP-0264901-B1 | Acylation products of bis(2-imidazolin-2-ylhydrazones) of 9,10-anthracenedicarboxaldehyde | AMERICAN CYANAMID CO (US) | 1994-08-10 | — | — | EP | disclosed |
| EP-0264901-A1 | Acylation products of bis(2-imidazolin-2-ylhydrazones) of 9,10-anthracenedicarboxaldehyde | AMERICAN CYANAMID COMPANY (US) | 1988-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210379021-A1 | METHOD FOR PREPARING AND DELIVERING BISANTRENE FORMULATIONS | CYP3A43, CYP1A1, UGT1A3 | ADRA2A 1586/4885ADRA1A 1146/4885HTR1A 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.